# Celloid Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celloid-co

- Industry: Biotechnology
- Headquarters: Pohang, South Korea
- Website: www.celloid.co.kr/
- Total disclosed funding: $0.4M
- Latest round: Seed (Dec 20, 2022)
- Investors on record: 2

## About

Based in Gyeonggi-do, South Korea, and founded in 2021, Celloid Co., Ltd. operates as a biotechnology company that develops a three-dimensional cell culture automation system for cell aggregates. In January 2024, the firm raised KRW 2.4 billion in pre-series A funding led by investor FuturePlay, with participation from another investor POSTECH Holdings. The firm as of January 2024, has an office in Gyeongsangbuk-do, and a research and development facility in Seoul, Republic of Korea, and is led by its CEO, Min Byeong-hyeok.

The company through its 3D cell culture technology offers homogeneity and reproducibility solutions in cell culture, advancing regenerative medicine, drug discovery, and disease modeling. The company's flagship products are NestWell® and OrgaNest®. NestWell® is an optimal platform with highly permeable microwells, facilitating a quality-controlled long-term culture of organoids. On the other hand, OrgaNest® offers high-throughput automated culture through a closed continuous perfusion system, bringing us a step closer to automated culture for cell therapy manufacturing.

## Funding rounds

- Seed, Dec 20, 2022, $0.4M — Korea Tech Incubator for Startup, POSTECH Holdings
- Seed, May 1, 2022 — POSTECH Holdings

## Investors

- POSTECH Holdings (https://capitalatlas.ai/funds/postech-holdings) — Seed
- Korea Tech Incubator for Startup — Seed